This study aimed to evaluate the efficacy of transurethral thulium laser en bloc resection of the bladder tumor (TmLRBT) in patients with non-muscle invasive bladder cancer (NMIBC) and to investigate whether a second resection can be avoided. From June 2012 to June 2018, 251 newly diagnosed patients with NMIBC were enrolled in this retrospective study; all patients received regular administration of pirarubicin after the initial resection. A second transurethral resection (TUR) was performed in patients within 2–6 weeks after the initial TmLRBT in group 1. Patients in group 2 only underwent cystoscopy at 3 months. Second surgery results indicate that recurrence was detected histopathologically in 6/108 and 11/143 patients in group 1 and 2, respectively (P = 0.52); Progression was observed in 2 patients in each group (P = 0.34). The mean follow-up duration was 40.1 months, with no significant difference between the groups (P = 0.32). Recurrence was observed in 23 (21.3%) and 39 (27.3%) patients in groups 1 and 2 during the follow-up, respectively (P = 0.34); disease progression occurred in 4 (3.8%) patients in group 1 compared with 7 (4.0%) in group 2 (P = 0.20). Complete removal of tumors can be achieved by TmLRBT. This technique may decrease the number of second TURs.

中文翻译：

---

对于非肌肉浸润性膀胱癌，初次laser激光内窥镜整块切除后可以避免再次切除吗？251名患者的回顾性单中心研究

这项研究旨在评估经尿道ure激光整形切除非肿瘤性膀胱癌（NMIBC）患者的膀胱肿瘤（TmLRBT），并研究是否可以避免再次切除。从2012年6月至2018年6月，该回顾性研究纳入了251名新诊断的NMIBC患者。初次切除后，所有患者均定期接受吡柔比星治疗。第1组在初次TmLRBT后2-6周内对患者进行第二次经尿道切除术（TUR）。第2组中的患者仅在3个月时接受了膀胱镜检查。第二次手术结果表明，第1组和第2组的6/108和11/143患者分别在组织病理学上检测到复发（P = 0.52）；每组中有2例患者出现了进展（P = 0.34）。平均随访时间为40.1个月，两组之间无显着差异（P = 0.32）。随访期间分别在第1组和第2组中23例（21.3％）和39例（27.3％）患者中观察到复发（P = 0.34）；第1组的4位患者（3.8％）发生了疾病进展，而第2组的7位患者（4.0％）发生了疾病（P = 0.20）。TmLRBT可以完全清除肿瘤。此技术可以减少第二个TUR的数量。